LIMITED LIABILITY COMPANY AGREEMENT OF ATOMWISE-STEMONIX JV1, LLC Dated as of November 27, 2019Limited Liability Company Agreement • February 8th, 2021 • Cancer Genetics, Inc • Services-medical laboratories • Delaware
LIMITED LIABILITY COMPANY AGREEMENT of Atomwise-StemoniX JV1, LLC, a Delaware limited liability company (the “Company”), dated as of November 27, 2019 (the “Effective Date”), by and among the Company, Atomwise Inc., a Delaware corporation having its principal place of business at 717 Market Street, Suite 800, San Francisco, CA 94103 (“Atomwise”), StemoniX Inc., a Minnesota corporation having its principal place of business at 13300 67th Ave N, Maple Grove, MN 55311 (“StemoniX”), and any other Members listed on Exhibit B hereto. The Company is organized under the Delaware Limited Liability Company Act, 6 Del. C. § 18-101, et seq.
Certain identified information has been excluded from the exhibit because it is both not material and would likely cause competitive harm if publicly disclosed. NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • February 8th, 2021 • Cancer Genetics, Inc • Services-medical laboratories
This Agreement is made effective as of the 19th day of January, 2016 (“Effective Date”) by and between StemoniX, Inc., a Minnesota corporation, with a principal place of business at 9081 Waverly Court, Eden Prairie, MN 55347, USA (hereinafter referred to as “LICENSEE”) and ID Pharma Co., Ltd., a Japan corporation, with a principal office at 6 Ohkubo, Tsukuba, Ibaraki 300-2611, Japan (hereinafter referred as “IDP”). LICENSEE and IDP may be referred to individually as a “Party” or collectively as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both not material and would likely cause competitive harm if publicly disclosed. Amended and Restated Non-Exclusive License AgreementLicense Agreement • February 8th, 2021 • Cancer Genetics, Inc • Services-medical laboratories
This Amended and Restated Non-Exclusive License Agreement (this “Agreement”) is made effective as of the 1st day of April, 2017 (the “Effective Date”) by and between iPS Academia Japan, Inc., a Japan corporation, with a principal office at 207 International Science Innovation Building East Wing, Kyoto University, 36-1 Yoshida-honmachi, Sakyo-ku, Kyoto, 606-8501 (“AJ”) and StemoniX, Inc., a Minnesota corporation, with a principal place of business at 13300 67th Ave N, Maple Grove, MN 55311, U.S.A. (“LICENSEE”). This Agreement amends and restates that certain Non-Exclusive License Agreement between AJ and LICENSEE effective as of December 22, 2015, as amended to date. AJ and LICENSEE may be referred to individually as a “Party” or collectively as the Parties”.
